L-Glutamine vs Zinc Carnosine — the enterocyte fuel and the mucosal adherent
Both are pitched at the same vague "leaky gut" / gut-healing audience, but they work on different tissues and have different evidence bases. L-glutamine is the primary metabolic fuel for enterocytes and immune cells; the cleanest RCT for a gut-specific indication is Zhou 2019 in post-infectious IBS-D. Zinc carnosine is a chelated complex that adheres to ulcerated gastric and intestinal mucosa, with the strongest evidence base in Japanese trials for peptic ulcer healing and NSAID-induced gastropathy. They aren't competitors — they sit at different points along the GI tract and serve different indications.
Quick verdict
| Goal | Better choice | Why |
|---|---|---|
| Post-infectious IBS-D (after gastro) | L-glutamine | Zhou 2019 (n=106, 5 g t.i.d. × 8 wk) showed meaningful symptom and stool-pattern improvement. |
| NSAID-induced small bowel injury | Zinc carnosine | RCTs show reduced small-bowel permeability and ulceration with zinc carnosine in NSAID users. |
| H. pylori adjunct | Zinc carnosine | Approved in Japan as H. pylori adjunct (Polaprezinc); modest eradication-rate improvement when added to triple therapy. |
| Functional dyspepsia / mild upper GI | Zinc carnosine | Targets gastric mucosa where the symptoms localise. |
| Critical illness / burn / trauma recovery | L-glutamine (under medical care) | ICU protocols include parenteral glutamine; oral supplementation evidence is mixed. |
| "Leaky gut" as a general goal | Neither alone | Address underlying drivers (diet, alcohol, NSAIDs, dysbiosis); both supplements are situational adjuncts at best. |
How they compare on biology
What L-glutamine does
L-glutamine is the most abundant free amino acid in plasma and the primary metabolic fuel for rapidly dividing cells — enterocytes, colonocytes, and lymphocytes. In healthy adults with sufficient dietary protein, plasma glutamine is amply supplied; in catabolic states (sepsis, burns, major surgery), it becomes conditionally essential. Mechanistically, glutamine supports tight-junction protein expression (occludin, ZO-1), maintains intestinal villus height in models of mucosal injury, and supports glutathione synthesis. The proposed gut-healing benefit is direct enterocyte nourishment plus barrier function support.
What zinc carnosine does
Zinc carnosine (polaprezinc, N-(3-aminopropionyl)-L-histidinato zinc) is a 1:1 chelate of zinc and L-carnosine. The unique pharmacology: it dissociates slowly in the acidic gastric environment and adheres directly to ulcer crater surfaces and inflamed gut mucosa, where it releases zinc locally as a healing cofactor. It is licensed in Japan as a gastric-ulcer treatment (Promac/Polaprezinc) and has substantial RCT evidence base in that indication. Mechanistically: free-radical scavenging at injured mucosa, induction of heat-shock proteins, antioxidant support, and direct zinc delivery for tissue repair.
Trial evidence — L-glutamine in IBS
Zhou 2019 (n=106, post-infectious IBS-D, 5 g t.i.d. × 8 weeks): primary endpoint (≥50-point IBS-SSS reduction) achieved in 79.6% glutamine vs 5.8% placebo. Reductions in stool frequency and Bristol score, and reductions in small-bowel permeability measured by lactulose-mannitol. Earlier exercise-induced "leaky gut" trials show similar permeability-reduction signals. The Zhou trial is the headline study and is much stronger evidence than the general "gut healing" marketing suggests.
Trial evidence — zinc carnosine
Hiraishi 1999 and other Japanese trials showed reduced gastric ulcer recurrence with 150 mg/day. Mahmood 2007 demonstrated reduced indomethacin-induced small-bowel permeability in healthy volunteers. Larger meta-analyses position zinc carnosine as a useful add-on for H. pylori triple/quadruple therapy with modest eradication-rate improvements. The trial portfolio is older but the indication is reasonably well-defined and outcome-focused.
Dosing
L-glutamine: 5 g t.i.d. (15 g/day total) is the Zhou 2019 protocol; lower doses (5 g/day) are commonly used outside post-infectious IBS but with weaker evidence. Dose is well above what's reached through diet alone. Zinc carnosine: 37.5 mg b.i.d. (75 mg/day total, ≈17 mg elemental zinc) is the Japan-licensed dose. Take on an empty stomach to maximise gastric mucosal adherence.
Safety
L-glutamine: very well tolerated; theoretical concern in advanced cancer (some tumours have high glutamine uptake) — discuss with oncologist if cancer history. Avoid in hepatic encephalopathy (can elevate ammonia). Zinc carnosine: well tolerated; the elemental zinc dose at 75 mg/day is meaningful — chronic high-dose zinc can cause copper deficiency. Standard duration of zinc carnosine use is 8 weeks; long-term continuous use requires copper monitoring or copper co-supplementation. Discuss with prescriber if on long-term zinc.
Who should consider supplementing
L-glutamine: post-infectious IBS-D meeting the Zhou trial profile; users with documented exercise-associated GI distress; critically ill users under medical supervision. Zinc carnosine: users with confirmed peptic ulcer disease (alongside standard PPI therapy), users with NSAID-induced GI injury who must continue NSAIDs, H. pylori-eradication adjuncts.
Who should skip
L-glutamine: active cancer (discuss with oncology), hepatic encephalopathy or advanced liver disease, users with adequate protein intake and no specific indication. Zinc carnosine: users already on high-dose zinc from other sources (>40 mg elemental zinc/day total without copper); pregnancy beyond physiologic zinc requirements without prescriber guidance.
What the price difference buys you
L-glutamine bulk powder at the Zhou dose (15 g/day): $0.50–1/day. Zinc carnosine 75 mg/day (Doctor's Best, NOW, Designs for Health): $0.70–1.50/day. Per dollar of trial-grade evidence, zinc carnosine is reasonably priced for its specific gastric indications; L-glutamine is reasonably priced for the Zhou IBS-D indication. Both are reasonable for the right user.
What we'd actually buy
For post-infectious IBS-D (confirmed prior gastro and ongoing IBS-D pattern): L-glutamine 5 g t.i.d. with meals for 8 weeks; reassess IBS-SSS at 4 and 8 weeks.
For NSAID gastropathy or H. pylori adjunct: zinc carnosine 37.5 mg b.i.d. on an empty stomach for 8 weeks. Coordinate with prescriber and standard GI care (PPI, H. pylori triple therapy as indicated).
For general "gut health" without a specific indication: neither — address the higher-evidence layer first (dietary pattern, fibre, alcohol, NSAIDs, sleep, stress), then evaluate whether a specific indication has emerged.
Sources
- Zhou Q, et al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019;68(6):996–1002. PMID: 30108163
- Mahmood A, et al. Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut. 2007;56(2):168–175. PMID: 16777920
- Hiraishi H, et al. Polaprezinc protects gastric mucosal cells from non-steroidal anti-inflammatory drug-induced injury. Aliment Pharmacol Ther. 1999;13 Suppl 1:74–81. PMID: 10209687
- Kim DJ, et al. Polaprezinc adjuvant therapy for H. pylori eradication: a meta-analysis. BMC Gastroenterol. 2018;18:69. PMID: 29776344
- Wang B, et al. Glutamine and intestinal barrier function. Amino Acids. 2015;47(10):2143–2154. PMID: 25069870
- Cruzat V, et al. Glutamine: metabolism and immune function, supplementation and clinical translation. Nutrients. 2018;10(11):1564. PMID: 30360490